[{"id":"6d19b3f0-4cc5-4aec-9cc7-a1e6cef5690a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00924196","created_at":"2021-01-18T03:34:45.955Z","updated_at":"2025-02-25T12:25:33.732Z","phase":"","brief_title":"Natural History Study of Patients With Neurofibromatosis Type I","source_id_and_acronym":"NCT00924196","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 259","initiation":"Initiation: 02/25/2008","start_date":" 02/25/2008","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-24"},{"id":"7a55dd21-17fa-4758-9f8c-76ac780a7858","acronym":"","url":"https://clinicaltrials.gov/study/NCT04750928","created_at":"2021-02-11T12:52:56.866Z","updated_at":"2025-02-25T12:27:56.800Z","phase":"Phase 1/2","brief_title":"Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas","source_id_and_acronym":"NCT04750928","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 11/29/2021","start_date":" 11/29/2021","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2025-02-24"},{"id":"a64e7059-51b9-4bf5-a1c3-321665846a5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02211768","created_at":"2021-01-18T10:21:36.289Z","updated_at":"2025-02-25T13:39:14.783Z","phase":"Phase 1","brief_title":"Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1","source_id_and_acronym":"NCT02211768","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 12/08/2014","start_date":" 12/08/2014","primary_txt":" Primary completion: 09/05/2017","primary_completion_date":" 09/05/2017","study_txt":" Completion: 12/30/2019","study_completion_date":" 12/30/2019","last_update_posted":"2025-02-21"},{"id":"e7e1d023-41dd-42ad-94c7-b3480955cb2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02544022","created_at":"2021-01-18T12:18:30.632Z","updated_at":"2025-02-25T15:42:35.186Z","phase":"","brief_title":"Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)","source_id_and_acronym":"NCT02544022","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 486","initiation":"Initiation: 11/13/2015","start_date":" 11/13/2015","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2025-02-11"},{"id":"b693b06c-3b76-4750-b15a-1fde2b2e9268","acronym":"SPRINT","url":"https://clinicaltrials.gov/study/NCT02407405","created_at":"2021-01-18T11:29:43.638Z","updated_at":"2025-02-25T17:29:15.429Z","phase":"Phase 2","brief_title":"MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas","source_id_and_acronym":"NCT02407405 - SPRINT","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Koselugo (selumetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/07/2016","start_date":" 01/07/2016","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2025-01-30"},{"id":"5e4005e8-2746-47c2-b8df-66fc536bfe6d","acronym":"RENEU","url":"https://clinicaltrials.gov/study/NCT03962543","created_at":"2021-01-18T19:29:52.226Z","updated_at":"2025-02-25T15:34:26.121Z","phase":"Phase 2","brief_title":"MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas","source_id_and_acronym":"NCT03962543 - RENEU","lead_sponsor":"SpringWorks Therapeutics, Inc.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gomekli (mirdametinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 09/29/2019","start_date":" 09/29/2019","primary_txt":" Primary completion: 09/20/2023","primary_completion_date":" 09/20/2023","study_txt":" Completion: 05/23/2025","study_completion_date":" 05/23/2025","last_update_posted":"2024-10-17"},{"id":"7ae39bae-f74c-4bd9-bb9c-b0ac08141f45","acronym":"","url":"https://clinicaltrials.gov/study/NCT04892017","created_at":"2021-05-19T15:52:38.986Z","updated_at":"2024-07-02T16:34:26.607Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of DCC-3116 in Patients With RAS/MAPK Pathway Mutant Solid Tumors","source_id_and_acronym":"NCT04892017","lead_sponsor":"Deciphera Pharmaceuticals LLC","biomarkers":" KRAS • BRAF • NRAS • NF1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • NRAS mutation • BRAF V600 • BRAF V600K • NF1 mutation • KRAS G12","tags":["KRAS • BRAF • NRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • NRAS mutation • BRAF V600 • BRAF V600K • NF1 mutation • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Lumakras (sotorasib) • Mektovi (binimetinib) • inlexisertib (DCC-3116)"],"overall_status":"Recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2024-06-13"},{"id":"b30a8bca-2be6-49b4-90f3-03ff7a00b1ad","acronym":"","url":"https://clinicaltrials.gov/study/NCT04586270","created_at":"2021-01-18T21:52:48.356Z","updated_at":"2024-07-02T16:34:37.959Z","phase":"Phase 1","brief_title":"A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer","source_id_and_acronym":"NCT04586270","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" HER-2 • KRAS • PTEN • NF1","pipe":" | ","alterations":" KRAS mutation • HR positive • KRAS G12C • HER-2 negative • KRAS G12D • NF1 mutation • KRAS G12 • HR positive + HER-2 negative","tags":["HER-2 • KRAS • PTEN • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HR positive • KRAS G12C • HER-2 negative • KRAS G12D • NF1 mutation • KRAS G12 • HR positive + HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TAS0612"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-06-05"},{"id":"4c83f544-8bf0-4858-908c-410296c3f0b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05804227","created_at":"2023-04-07T13:03:03.068Z","updated_at":"2024-07-02T16:34:59.598Z","phase":"Phase 1","brief_title":"Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults","source_id_and_acronym":"NCT05804227","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ulixertinib (BVD-523)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/20/2023","start_date":" 04/20/2023","primary_txt":" Primary completion: 09/22/2025","primary_completion_date":" 09/22/2025","study_txt":" Completion: 09/22/2027","study_completion_date":" 09/22/2027","last_update_posted":"2024-06-03"},{"id":"02eaf617-0513-44fc-bea7-b3c0c01ecd8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05849662","created_at":"2023-05-09T14:04:18.433Z","updated_at":"2024-07-02T16:35:02.520Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia","source_id_and_acronym":"NCT05849662","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" KRAS • NRAS • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation","tags":["KRAS • NRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • cytarabine • azacitidine • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 05/10/2024","start_date":" 05/10/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-05-20"},{"id":"7315975a-48e7-478f-a922-63b5c722e7c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03872427","created_at":"2021-01-18T19:05:39.832Z","updated_at":"2024-07-02T16:35:03.365Z","phase":"Phase 2","brief_title":"Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study","source_id_and_acronym":"NCT03872427","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" STK11 • NF1 • KEAP1 • NFE2L2","pipe":" | ","alterations":" STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation","tags":["STK11 • NF1 • KEAP1 • NFE2L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation • NF1 mutation • KEAP1 mutation • NFE2L2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e telaglenastat (CB-839)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 12/14/2019","start_date":" 12/14/2019","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2024-05-16"},{"id":"6ab65671-28fd-4a23-bc0c-3d5205104b75","acronym":"PRiME","url":"https://clinicaltrials.gov/study/NCT03299309","created_at":"2021-01-18T16:18:00.321Z","updated_at":"2024-07-02T16:35:04.405Z","phase":"Phase 1","brief_title":"PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma","source_id_and_acronym":"NCT03299309 - PRiME","lead_sponsor":"Daniel Landi","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/29/2018","start_date":" 06/29/2018","primary_txt":" Primary completion: 04/27/2023","primary_completion_date":" 04/27/2023","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-05-10"},{"id":"3b52b9d4-20d4-4a79-a816-f21eb9b91b3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807932","created_at":"2023-04-11T14:03:36.196Z","updated_at":"2024-07-02T16:35:06.548Z","phase":"Phase 1/2","brief_title":"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","source_id_and_acronym":"NCT05807932","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" KRAS • TP53 • NRAS • IDH1 • IDH2 • NF1 • RUNX1 • KMT2A • PTPN11 • NUP214 • DEK • RIT1","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation • CBL mutation","tags":["KRAS • TP53 • NRAS • IDH1 • IDH2 • NF1 • RUNX1 • KMT2A • PTPN11 • NUP214 • DEK • RIT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • fludarabine IV • Grafapex (treosulfan) • Amsidine (amsacrine)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/30/2028","study_completion_date":" 01/30/2028","last_update_posted":"2024-05-01"},{"id":"8d11e7de-5fd7-49f6-b0e9-31e7346e7fd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04800822","created_at":"2021-03-16T14:52:26.431Z","updated_at":"2024-07-02T16:35:06.982Z","phase":"Phase 1","brief_title":"PF-07284892 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04800822","lead_sponsor":"Pfizer","biomarkers":" ALK • ROS1 • NF1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive","tags":["ALK • ROS1 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • ALK positive • NF1 mutation • RAS mutation • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Lorbrena (lorlatinib) • Mektovi (binimetinib) • Braftovi (encorafenib) • PF-07284892"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 03/17/2021","start_date":" 03/17/2021","primary_txt":" Primary completion: 06/18/2024","primary_completion_date":" 06/18/2024","study_txt":" Completion: 11/29/2025","study_completion_date":" 11/29/2025","last_update_posted":"2024-04-30"},{"id":"84233739-ed53-4cf9-9895-5c8bd3e952d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03043391","created_at":"2021-01-18T14:59:13.296Z","updated_at":"2024-07-02T16:35:10.938Z","phase":"Phase 1","brief_title":"Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children","source_id_and_acronym":"NCT03043391","lead_sponsor":"Istari Oncology, Inc.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lerapolturev (PVS-RIPO)"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 11/07/2017","start_date":" 11/07/2017","primary_txt":" Primary completion: 03/23/2022","primary_completion_date":" 03/23/2022","study_txt":" Completion: 03/23/2022","study_completion_date":" 03/23/2022","last_update_posted":"2024-04-08"},{"id":"57d72b12-2ee4-465b-8e35-96a6d9527fcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03594422","created_at":"2021-01-18T17:40:27.278Z","updated_at":"2024-07-02T16:35:14.185Z","phase":"Phase 1","brief_title":"A Study of HQP1351 in Patients With GIST or Other Solid Tumors","source_id_and_acronym":"NCT03594422","lead_sponsor":"Ascentage Pharma Group Inc.","biomarkers":" NF1 • SDHB","pipe":" | ","alterations":" NF1 mutation","tags":["NF1 • SDHB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nailike (olverembatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/11/2018","start_date":" 07/11/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-03-19"},{"id":"8f8e9487-9ee4-4fb4-9fb0-f22de3968e90","acronym":"NF111","url":"https://clinicaltrials.gov/study/NCT04544007","created_at":"2021-01-18T21:44:13.649Z","updated_at":"2024-07-02T16:35:14.441Z","phase":"Phase 2","brief_title":"A Phase II Trial of Poly-ICLC for Low-Grade Gliomas","source_id_and_acronym":"NCT04544007 - NF111","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/15/2021","start_date":" 12/15/2021","primary_txt":" Primary completion: 02/15/2026","primary_completion_date":" 02/15/2026","study_txt":" Completion: 02/15/2027","study_completion_date":" 02/15/2027","last_update_posted":"2024-03-15"},{"id":"b4509b46-cf96-4a36-af86-5a28202e4c9b","acronym":"CONCERTO","url":"https://clinicaltrials.gov/study/NCT04409639","created_at":"2021-01-18T21:15:48.018Z","updated_at":"2024-07-02T16:35:17.291Z","phase":"Phase 2","brief_title":"Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations","source_id_and_acronym":"NCT04409639 - CONCERTO","lead_sponsor":"University of Utah","biomarkers":" KRAS • BRAF • FLT3 • NRAS • NF1 • JAK2 • PTPN11","pipe":" | ","alterations":" BRAF mutation • NF1 mutation","tags":["KRAS • BRAF • FLT3 • NRAS • NF1 • JAK2 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 01/12/2021","start_date":" 01/12/2021","primary_txt":" Primary completion: 08/15/2025","primary_completion_date":" 08/15/2025","study_txt":" Completion: 08/15/2026","study_completion_date":" 08/15/2026","last_update_posted":"2024-02-28"},{"id":"afe413d7-7e85-457e-9af3-9c556a34d9ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT01396408","created_at":"2021-01-18T05:44:09.814Z","updated_at":"2024-07-02T16:35:17.762Z","phase":"Phase 2","brief_title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT01396408","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PTEN • STK11 • NF1","pipe":" | ","alterations":" EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification","tags":["PTEN • STK11 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • temsirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 02/09/2012","start_date":" 02/09/2012","primary_txt":" Primary completion: 07/06/2015","primary_completion_date":" 07/06/2015","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-26"},{"id":"0ffce0fc-79c3-4a90-be92-5ef083953437","acronym":"Re-MATCH","url":"https://clinicaltrials.gov/study/NCT01326104","created_at":"2021-01-18T05:24:06.638Z","updated_at":"2024-07-02T16:35:18.013Z","phase":"Phase 2","brief_title":"Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor","source_id_and_acronym":"NCT01326104 - Re-MATCH","lead_sponsor":"University of Florida","biomarkers":" NF1 • CD34","pipe":" | ","alterations":" NF1 mutation","tags":["NF1 • CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/07/2010","start_date":" 09/07/2010","primary_txt":" Primary completion: 03/28/2020","primary_completion_date":" 03/28/2020","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2024-02-23"},{"id":"4ae47410-6462-4c48-be2b-e65000130da1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03332030","created_at":"2021-01-18T16:27:14.393Z","updated_at":"2024-07-02T16:35:20.391Z","phase":"","brief_title":"Stem Cells in NF1 Patients With Tumors of the Central Nervous System","source_id_and_acronym":"NCT03332030","lead_sponsor":"Roger Packer","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/27/2015","start_date":" 11/27/2015","primary_txt":" Primary completion: 02/05/2024","primary_completion_date":" 02/05/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-02-07"},{"id":"5cdbdbf3-e8da-4789-91ba-999fa7089d8e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454035","created_at":"2021-01-18T17:01:52.689Z","updated_at":"2024-07-02T16:35:22.023Z","phase":"Phase 1","brief_title":"Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors","source_id_and_acronym":"NCT03454035","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" KRAS • BRAF • NRAS • HRAS • NF1","pipe":" | ","alterations":" BRAF V600 • NF1 mutation • RAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • KRAS amplification • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61","tags":["KRAS • BRAF • NRAS • HRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • NF1 mutation • RAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • KRAS amplification • NRAS G12 • NRAS G13 • KRAS Q61 • HRAS Q61"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • ulixertinib (BVD-523)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 01/30/2018","start_date":" 01/30/2018","primary_txt":" Primary completion: 07/15/2024","primary_completion_date":" 07/15/2024","study_txt":" Completion: 04/24/2026","study_completion_date":" 04/24/2026","last_update_posted":"2024-01-26"},{"id":"68535bad-a0b1-4d63-be97-8d1293540775","acronym":"NF108-BINI","url":"https://clinicaltrials.gov/study/NCT03231306","created_at":"2021-01-18T15:56:47.258Z","updated_at":"2024-07-02T16:35:25.494Z","phase":"Phase 2","brief_title":"Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas","source_id_and_acronym":"NCT03231306 - NF108-BINI","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mektovi (binimetinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/28/2017","start_date":" 11/28/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-12-21"},{"id":"04cc697b-a936-4795-aed4-1231c763328e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05441514","created_at":"2022-07-01T20:56:41.287Z","updated_at":"2024-07-02T16:35:25.985Z","phase":"Phase 1","brief_title":"Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05441514","lead_sponsor":"City of Hope Medical Center","biomarkers":" KRAS • BRAF • NRAS • IDH2 • NF1 • PTPN11","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • IDH2 mutation • NF1 mutation • RAS mutation • CBL mutation • IDH2 R140 • IDH2 R172","tags":["KRAS • BRAF • NRAS • IDH2 • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • IDH2 mutation • NF1 mutation • RAS mutation • CBL mutation • IDH2 R140 • IDH2 R172"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cotellic (cobimetinib) • Idhifa (enasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 05/02/2025","study_completion_date":" 05/02/2025","last_update_posted":"2023-12-18"}]